Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Vigabatrin

Raman Singh  1 , Robert P. Carson  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Vigabatrin

Raman Singh et al.
Free Books & Documents

Excerpt

Vigabatrin is an antiepileptic drug primarily used to manage infantile spasms and refractory complex partial seizures. This medication functions as an irreversible inhibitor of GABA transaminase, increasing GABA levels in the brain, which helps control seizure activity. Indications include infantile spasms and cases of epilepsy that do not respond to other treatments. Vigabatrin is associated with significant adverse effects, including visual field defects, which have led to an FDA-issued box warning. Due to these risks, routine visual monitoring is essential during treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Raman Singh declares no relevant financial relationships with ineligible companies.

Disclosure: Robert Carson declares no relevant financial relationships with ineligible companies.

References

    1. Foroozan R. Vigabatrin: Lessons Learned From the United States Experience. J Neuroophthalmol. 2018 Dec;38(4):442-450. - PubMed
    1. Tolman JA, Faulkner MA. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opin Pharmacother. 2009 Dec;10(18):3077-89. - PubMed
    1. Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, Frost MD, Fuchs Z, Gosnell ES, Gupta N, Jansen AC, Jóźwiak S, Kingswood JC, Knilans TK, McCormack FX, Pounders A, Roberds SL, Rodriguez-Buritica DF, Roth J, Sampson JR, Sparagana S, Thiele EA, Weiner HL, Wheless JW, Towbin AJ, Krueger DA, International Tuberous Sclerosis Complex Consensus Group Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021 Oct;123:50-66. - PubMed
    1. Prezioso G, Chiarelli F, Matricardi S. Efficacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: a systematic review. Expert Rev Neurother. 2023 Jul-Dec;23(7):661-671. - PubMed
    1. Xu Z, Gong P, Jiao X, Niu Y, Wu Y, Zhang Y, Chang X, Yang Z. Efficacy of vigabatrin in the treatment of infantile epileptic spasms syndrome: A systematic review and meta-analysis. Epilepsia Open. 2023 Jun;8(2):268-277. - PMC - PubMed

Publication types

LinkOut - more resources